Experimental CAR T-Cell therapy takes on relapsed leukemia

NCT ID NCT07471789

First seen Mar 19, 2026 · Last updated Apr 29, 2026 · Updated 4 times

Summary

This study tests an experimental treatment called GYA01 (CART84) for people with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better attack leukemia cells, and then infused back. The goal is to find a safe dose and see if it can help control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOBLASTIC LEUKAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Hospital Clínic de Barcelona

    RECRUITING

    Barcelona, Barcelona, 08036, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitario y Politécnico La Fe

    RECRUITING

    Valencia, Valencia, 46026, Spain

    Contact Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.